AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
John Leonard
Consultant or Advisory Role - Celgene
John G. Gribben
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Roche
Marek Trneny
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Phillip Scheinberg
No relevant relationships to disclose
Nurgul Kilavuz
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Meera Patturajan
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Pierre Fustier
Employment or Leadership Position - Celgene
Stock Ownership - Celgene